1
|
Ubhi H, Ferro A, Ebelthite C, Fan K. Predictive risk factors of adverse mental health outcomes in the facial trauma patient. Int J Oral Maxillofac Surg 2024:S0901-5027(24)00089-4. [PMID: 38637181 DOI: 10.1016/j.ijom.2024.03.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/26/2023] [Revised: 03/24/2024] [Accepted: 03/27/2024] [Indexed: 04/20/2024]
Abstract
Patients with facial trauma often experience a psychological burden from their injuries. This study aimed to identify risk factors for adverse mental health outcomes in patients affected by facial trauma, using the 'Integrating Mental and Physical Healthcare: Research, Training and Services' (IMPARTS) screening tool. All patients >18 years of age who completed more than one IMPARTS screening tool in the Oral and Maxillofacial Trauma Clinic between 2019 and 2021 were included in this study. This tool was used to assess the risk of post-traumatic stress disorder (PTSD), generalized anxiety disorder, and depression. Included patients completed the IMPARTS questionnaire at initial follow-up (mean 18 days post-trauma) and one subsequent time point (mean 82 days). 167 patients were included in the study. On multivariable analysis, a history of psychiatric illness (P = 0.015) and interpersonal violence as the mechanism of injury (P = 0.010) were identified as predictive of risk of PTSD. Risk of PTSD was lower in zygomatic injuries (P = 0.001), while nasal involvement increased at-risk status for depression (P = 0.009). 47.3% of patients screened positive on initial IMPARTS assessment, while 35.3% screened positive on follow-up IMPARTS assessment. This study supports the IMPARTS tool in allowing the prompt identification of mental health adversity in facial trauma.
Collapse
Affiliation(s)
- H Ubhi
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, London, UK; Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK
| | - A Ferro
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, London, UK; Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK
| | - C Ebelthite
- IMPARTS Mind and Body Programme, Psychological Medicine and Integrated Care Clinical Academic Group, King's College London, London, UK
| | - K Fan
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, London, UK; Faculty of Dentistry, Oral and Craniofacial Sciences, King's College London, London, UK.
| |
Collapse
|
2
|
Ferro A, Arshad A, Boyd L, Stanley T, Berisha A, Vrudhula U, Gomez AM, Borniger JC, Cheadle L. The cytokine receptor Fn14 is a molecular brake on neuronal activity that mediates circadian function in vivo. bioRxiv 2024:2024.04.02.587786. [PMID: 38617238 PMCID: PMC11014623 DOI: 10.1101/2024.04.02.587786] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 04/16/2024]
Abstract
To survive, organisms must adapt to a staggering diversity of environmental signals, ranging from sensory information to pathogenic infection, across the lifespan. At the same time, organisms intrinsically generate biological oscillations, such as circadian rhythms, without input from the environment. While the nervous system is well-suited to integrate extrinsic and intrinsic cues, how the brain balances these influences to shape biological function system-wide is not well understood at the molecular level. Here, we demonstrate that the cytokine receptor Fn14, previously identified as a mediator of sensory experience-dependent synaptic refinement during brain development, regulates neuronal activity and function in adult mice in a time-of-day-dependent manner. We show that a subset of excitatory pyramidal (PYR) neurons in the CA1 subregion of the hippocampus increase Fn14 expression when neuronal activity is heightened. Once expressed, Fn14 constrains the activity of these same PYR neurons, suggesting that Fn14 operates as a molecular brake on neuronal activity. Strikingly, differences in PYR neuron activity between mice lacking or expressing Fn14 were most robust at daily transitions between light and dark, and genetic ablation of Fn14 caused aberrations in circadian rhythms, sleep-wake states, and sensory-cued and spatial memory. At the cellular level, microglia contacted fewer, but larger, excitatory synapses in CA1 in the absence of Fn14, suggesting that these brain-resident immune cells may dampen neuronal activity by modifying synaptic inputs onto PYR neurons. Finally, mice lacking Fn14 exhibited heightened susceptibility to chemically induced seizures, implicating Fn14 in disorders characterized by hyperexcitation, such as epilepsy. Altogether, these findings reveal that cytokine receptors that mediates inflammation in the periphery, such as Fn14, can also play major roles in healthy neurological function in the adult brain downstream of both extrinsic and intrinsic cues.
Collapse
Affiliation(s)
- Austin Ferro
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | - Anosha Arshad
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
- Department of Neurobiology and Behavior, Stony Brook University Renaissance School of Medicine, Stony Brook, NY 11794, USA
| | - Leah Boyd
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | - Tess Stanley
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | - Adrian Berisha
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | - Uma Vrudhula
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | - Adrian M. Gomez
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
| | | | - Lucas Cheadle
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 11740, USA
- Howard Hughes Medical Institute, Cold Spring Harbor, NY 11740, USA
| |
Collapse
|
3
|
Kahng JA, Xavier AM, Ferro A, Auguste YS, Cheadle L. Integrated high-confidence and high-throughput approaches for quantifying synapse engulfment by oligodendrocyte precursor cells. bioRxiv 2023:2023.08.24.554663. [PMID: 37662250 PMCID: PMC10473697 DOI: 10.1101/2023.08.24.554663] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/05/2023]
Abstract
Oligodendrocyte precursor cells (OPCs) sculpt neural circuits through the phagocytic engulfment of synapses during development and in adulthood. However, precise techniques for analyzing synapse engulfment by OPCs are limited. Here, we describe a two-pronged cell biological approach for quantifying synapse engulfment by OPCs which merges low- and high-throughput methodologies. In the first method, an adeno-associated virus encoding a pH-sensitive, fluorescently-tagged synaptic marker is expressed in neurons in vivo. This construct allows for the differential labeling of presynaptic inputs that are contained outside of and within acidic phagolysosomal compartments. When followed by immunostaining for markers of OPCs and synapses in lightly fixed tissue, this approach enables the quantification of synapses engulfed by around 30-50 OPCs within a given experiment. In the second method, OPCs isolated from dissociated brain tissue are fixed, incubated with fluorescent antibodies against presynaptic proteins, and then analyzed by flow cytometry. This approach enables the quantification of presynaptic material within tens of thousands of OPCs in less than one week. These methods extend beyond the current imaging-based engulfment assays designed to quantify synaptic phagocytosis by brain-resident immune cells, microglia. Through the integration of these methods, the engulfment of synapses by OPCs can be rigorously quantified at both the individual and populational levels. With minor modifications, these approaches can be adapted to study synaptic phagocytosis by numerous glial cell types in the brain.
Collapse
Affiliation(s)
- Jessica A. Kahng
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
- School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
| | | | - Austin Ferro
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
| | | | - Lucas Cheadle
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 11724
| |
Collapse
|
4
|
Hassanzadeh H, Ferro A, Woods K, Baring T. Review of the national usage of antibiotics in arthroplasty surgery: a need for evidence-based prescribing. Ann R Coll Surg Engl 2023. [PMID: 37381757 DOI: 10.1308/rcsann.2022.0145] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/30/2023] Open
Abstract
INTRODUCTION Surgical site infections (SSI) remain one of the most serious complications of arthroplasty surgery. The role of antibiotic prophylaxis in preventing SSI post-arthroplasty is well established. However, there is considerable heterogeneity in prophylactic prescribing across the United Kingdom (UK), which is contradicted by the contemporaneous evidence. This descriptive study aimed to compare the current first-line antibiotic recommendations across hospitals in the UK and The Republic of Ireland for elective arthroplasty procedures. METHODS The MicroGuide mobile phone application was used to access hospital antibiotic guidelines. First-line antibiotic recommendation and dosing regimen for primary elective arthroplasties were recorded. FINDINGS A total of nine distinct antibiotic regimens were identified through our search. The most frequently used first-line antibiotic was cefuroxime. This was recommended by 30 of the 83 (36.1%) hospitals in the study. This was followed by a combination of flucloxacillin and gentamicin, which was used by 38 of 124 (31%) hospitals. There was also significant heterogeneity in dosing regimens. A single prophylactic dose was most commonly recommended (52%); 4% of hospitals recommended two prophylactic doses, 19% three doses and 23% four doses. CONCLUSIONS Single-dose prophylaxis is recognised as at least noninferior to multiple-dose prophylaxis in primary arthroplasty. There is considerable variation in the local antibiotic recommendations for surgical site prophylaxis post-primary arthroplasty surgery, with respect to both recommended first-line antibiotic and dosing regimens. With increasing emphasis on the importance of antibiotic stewardship and the emergence of antibiotic resistance, this study highlights the need for an evidence-based approach to prophylactic dosing across the UK.
Collapse
Affiliation(s)
- H Hassanzadeh
- Homerton University Hospital NHS Foundation Trust, UK
| | - A Ferro
- Homerton University Hospital NHS Foundation Trust, UK
| | - K Woods
- Homerton University Hospital NHS Foundation Trust, UK
| | - T Baring
- Homerton University Hospital NHS Foundation Trust, UK
| |
Collapse
|
5
|
Marcuzzi D, Toigo V, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Pasqualotto R, Pavei M, Serianni G, Zanotto L, Agnello R, Agostinetti P, Agostini M, Aprile D, Barbisan M, Battistella M, Berton G, Bigi M, Brombin M, Candela V, Candeloro V, Canton A, Casagrande R, Cavallini C, Cavazzana R, Cordaro L, Cruz N, Dalla Palma M, Dan M, De Lorenzi A, Delogu R, De Muri M, De Nardi M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gasparrini C, Gnesotto F, Jain P, La Rosa A, Lopez-Bruna D, Lorenzini R, Maistrello A, Manduchi G, Manfrin S, Marconato N, Mario I, Martini G, Milazzo R, Patton T, Peruzzo S, Pilan N, Pimazzoni A, Poggi C, Pomaro N, Pouradier-Duteil B, Recchia M, Rigoni-Garola A, Rizzetto D, Rizzolo A, Santoro F, Sartori E, Segalini B, Shepherd A, Siragusa M, Sonato P, Sottocornola A, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Tomsič P, Trevisan L, Ugoletti M, Valente M, Valisa M, Veronese F, Vignando M, Zaccaria P, Zagorski R, Zaniol B, Zaupa M, Zuin M, Cavenago M, Boilson D, Rotti C, Decamps H, Geli F, Sharma A, Veltri P, Zacks J, Simon M, Paolucci F, Garbuglia A, Gutierrez D, Masiello A, Mico G, Labate C, Readman P, Bragulat E, Bailly-Maitre L, Gomez G, Kouzmenko G, Albajar F, Kashiwagi M, Tobari H, Kojima A, Murayama M, Hatakeyama S, Oshita E, Maejima T, Shibata N, Yamashita Y, Watanabe K, Singh N, Singh M, Dhola H, Fantz U, Heinemann B, Wimmer C, Wünderlich D, Tsumori K, Croci G, Gorini G, Muraro A, Rebai M, Tardocchi M, Giacomelli L, Rigamonti D, Taccogna F, Bruno D, Rutigliano M, Longo S, Deambrosis S, Miorin E, Montagner F, Tonti A, Panin F. Lessons learned after three years of SPIDER operation and the first MITICA integrated tests. Fusion Engineering and Design 2023. [DOI: 10.1016/j.fusengdes.2023.113590] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/27/2023]
|
6
|
Pasello G, Lorenzi M, Tosi A, Roma A, Pavan A, Scapinello A, Lonardi S, Ferro A, Maso AD, Frega S, Bonanno L, Del Bianco P, Guarneri V, Rosato A. 164P Immune cells distribution and spatial relationship within microenvironment as predictive biomarkers of benefit in extended stage small cell lung cancer patients receiving atezolizumab plus carboplatin and etoposide as first-line treatment. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00418-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/04/2023]
|
7
|
Del Mastro L, Poggio F, Blondeaux E, De Placido S, Giuliano M, Forestieri V, De Laurentiis M, Gravina A, Bisagni G, Rimanti A, Turletti A, Nisticò C, Vaccaro A, Cognetti F, Fabi A, Gasparro S, Garrone O, Alicicco MG, Urracci Y, Mansutti M, Poletti P, Correale P, Bighin C, Puglisi F, Montemurro F, Colantuoni G, Lambertini M, Boni L, Venturini M, Abate A, Pastorino S, Canavese G, Vecchio C, Guenzi M, Lambertini M, Levaggi A, Giraudi S, Accortanzo V, Floris C, Aitini E, Fornari G, Miraglia S, Buonfanti G, Cherchi M, Petrelli F, Vaccaro A, Magnolfi E, Contu A, Labianca R, Parisi A, Basurto C, Cappuzzo F, Merlano M, Russo S, Mansutti M, Poletto E, Nardi M, Grasso D, Fontana A, Isa L, Comandè M, Cavanna L, Iacobelli S, Milani S, Mustacchi G, Venturini S, Scinto A, Sarobba M, Pugliese P, Bernardo A, Pavese I, Coccaro M, Massidda B, Ionta M, Nuzzo A, Laudadio L, Chiantera V, Dottori R, Barduagni M, Castiglione F, Ciardiello F, Tinessa V, Ficorella A, Moscetti L, Vallini I, Giardina G, Silva R, Montedoro M, Seles E, Morano F, Cruciani G, Adamo V, Pancotti A, Palmisani V, Ruggeri A, Cammilluzzi E, Carrozza F, D'Aprile M, Brunetti M, Gallotti P, Chiesa E, Testore F, D'Arco A, Ferro A, Jirillo A, Pezzoli M, Scambia G, Iacono C, Masullo P, Tomasello G, Gandini G, Zoboli A, Bottero C, Cazzaniga M, Genua G, Palazzo S, D'Amico M, Perrone D. Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trial. Lancet Oncol 2022; 23:1571-1582. [DOI: 10.1016/s1470-2045(22)00632-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/16/2022] [Revised: 10/06/2022] [Accepted: 10/07/2022] [Indexed: 11/11/2022]
|
8
|
Auguste YSS, Ferro A, Kahng JA, Xavier AM, Dixon JR, Vrudhula U, Nichitiu AS, Rosado D, Wee TL, Pedmale UV, Cheadle L. Oligodendrocyte precursor cells engulf synapses during circuit remodeling in mice. Nat Neurosci 2022; 25:1273-1278. [PMID: 36171430 PMCID: PMC9534756 DOI: 10.1038/s41593-022-01170-x] [Citation(s) in RCA: 43] [Impact Index Per Article: 21.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Accepted: 08/18/2022] [Indexed: 01/13/2023]
Abstract
Oligodendrocyte precursor cells (OPCs) give rise to myelinating oligodendrocytes throughout life, but the functions of OPCs are not limited to oligodendrogenesis. Here we show that OPCs contribute to thalamocortical presynapse elimination in the developing and adult mouse visual cortex. OPC-mediated synapse engulfment increases in response to sensory experience during neural circuit refinement. Our data suggest that OPCs may regulate synaptic connectivity in the brain independently of oligodendrogenesis.
Collapse
Affiliation(s)
| | - Austin Ferro
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | - Jessica A Kahng
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.,School of Biological Sciences, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | - Andre M Xavier
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | | | - Uma Vrudhula
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | | | - Daniele Rosado
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | - Tse-Luen Wee
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
| | | | - Lucas Cheadle
- Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA.
| |
Collapse
|
9
|
Ferro A, Girardi F, Pretelli G, Mulargiu C, Resi M, Benetti B, Marinato G, Lorenzi M, Dal Maso A, Frega S, Pasello G, Guarneri V, Bonanno L. 1584P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) in a real-world analysis: A risk prediction nomogram. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
10
|
Lorenzi M, Scattolin D, Del Conte A, Sangiorgi S, Polo V, Pavan A, Pilotto S, Santarpia M, Da Ros V, Maso AD, Ferro A, Frega S, Bortolami A, Bonanno L, Indraccolo S, Guarneri V, Pasello G. EP08.02-104 Osimertinib in Untreated EGFR-Mutant Non-small Cell Lung Cancers: Overall Survival and Budget Impact Analysis in Real-World. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
11
|
Ferro A, Cheadle L. When the levee of sympathetic outflow breaks. Immunity 2022; 55:1334-1336. [DOI: 10.1016/j.immuni.2022.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
12
|
Lordi R, Veronese S, Piccinini A, Ferro A, Zerbini V, Piva T, Raisi A, Mandini S, Grazzi G, Sassone B, Pasanisi G. P370 INNOVATIVE TELEMONITORED MODEL OF PHYSICAL EXERCISE PRESCRIPTION IN SECONDARY PREVENTION DURING THE QUARANTINE. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.356] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022]
Abstract
Abstract
Introduction
COVID–19 pandemic induced the emanation of extraordinary measures like quarantine, that can be considered a risk factor for both physical and mental health in the population. In particular, gym’s closure and the need to stay home didn’t allow people to perform physical activity easily, with a consequent worsening of cardiovascular risk factors. During quarantine some general recommendations have been disseminated, but little is known about specific guidelines for home–based exercise prescription in patients with cardiovascular disease. Therefore, the purpose of this study is to develop home–based physical exercise programs for cardiac patients referred to the Center for Exercise Science and Sports of University of Ferrara.
Methods
On the basis of exercise capacity obtained from the last functional evaluation, performed in presence before the closure, three structured workouts were realized following the guidelines. They are composed as follows: warm–up, strenght and balance exercises alternate to indoor walking, cool–down. Patients received an explicative iconographic via e–mail or smartphone. Some domiciliary sessions were supervised by an operator through video connection.
Results
All patients showed excellent compliance with the proposed program. Adherence has been verified through biweekly recalls. No adverse events occurred.
Conclusions
Telemonitored exercise prescription in cardiac outpatients was effective and safe, helping to prevent negative consequences of the abrupt cessation of physical activity due to COVID–19 pandemic. These evidence could be useful even after the end of pandemic, for all those patients that are less likely to participate in traditional cardiovascular rehabilitation programs because of difficulties in reaching facilities or leaving home.
Collapse
Affiliation(s)
- R Lordi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - S Veronese
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - A Piccinini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - A Ferro
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - V Zerbini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - T Piva
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - A Raisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - S Mandini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - G Grazzi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - B Sassone
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| | - G Pasanisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, FERRARA; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND
| |
Collapse
|
13
|
Lordi R, Veronese S, Ferro A, Piccinini A, Piva T, Zerbini V, Raisi A, Mandini S, Grazzi G, Sassone B, Pasanisi G. P401 REMOTE COUNSELING ROLE DURING COVID–19 PANDEMIC IN SECONDARY PREVENTION AFTER ACUTE CORONARY SYNDROME. Eur Heart J Suppl 2022. [PMCID: PMC9384009 DOI: 10.1093/eurheartj/suac012.387] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Introduction Patients affected by acute coronary syndrome are usually referred to center–based secondary prevention programs where they are enrolled in physical activity programs and received indications about cardiovascular risk factors control. COVID–19 pandemic induced the emanation of restrictions in people’s mobility, ban on gathering and the obligation of social distancing. This made it difficult to maintain such group meetings in presence. Methods After hospitalization for acute coronary syndrome in Cardiology Unit of the AUSL of Ferrara, patients equipped with electronic devices were allowed to participate to remote counseling meetings on the digital platform LifesizeC. To improve participation, meetings were organized monthly (in order to gradually include new discharged patients) and involving caregivers (if patients weren’t able to access the web app). Information on regular physical activity benefits were provided. In particular, the F.I.T.T. principle (Frequency, Intensity, Type, Time) has been explained and Borg’s exertion scale was illustrated to be used in autonomy. Furthermore, there were provided recommendations about the need of a proper warm– up/cool–down, the possibility to wear a heart rate monitor and the early recognition of symptoms and warning signs. To complete health education, there were given information about correct nutrition, risk factors control and correct assumption of pharmacological therapy. Results All patients showed interest in the topics analyzed, asking various questions during the meetings. They also stated that they were strongly motivated to undertake regular physical activity having received convincing explanations on its usefulness and safety. Conclusions Remote counseling meetings obtained a high approval rating and the moments of discussion with the speakers were particularly well attended. The prescription of physical exercise in secondary prevention can follow innovative telemonitored approaches, which could be maintained even after COVID–19.
Collapse
Affiliation(s)
- R Lordi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - S Veronese
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Ferro
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Piccinini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - T Piva
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - V Zerbini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Raisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - S Mandini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - G Grazzi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - B Sassone
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - G Pasanisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| |
Collapse
|
14
|
Lordi R, Veronese S, Mandini S, Raisi A, Piccinini A, Ferro A, Zerbini V, Piva T, Grazzi G, Biagio S, Pasanisi G. P422 EARLY EXERCISE PRESCRIPTION AFTER ACUTE CORONARY SINDROME. A NEW MODEL FROM BEDSIDE TO THE COMMUNITY. Eur Heart J Suppl 2022. [DOI: 10.1093/eurheartj/suac012.406] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Abstract
Purpose
Physical inactivity is a major risk factor and negative prognostic index of cardiovascular disease. It is necessary to define effective strategies to direct patients after an acute coronary syndrome (ACS) to physically active lifestyle. The aim of this study was to examin efficacy, feasibility and long term adherence of a new physical activity prescription, adapted to patients (pts) early after ACS.
Methods
34 pts, mean age 67years, hospitalized for ACS, were enrolled consecutively and randomized 2:1 in treatment (TR) group (n = 23) or in control (CT) group. All pts were evaluated before discharge from hospital (T0) through Quality of Life (QoL) SF12 questionnaire, determination of physical activity during free time, six–minute walking test (6MWT). All pts were orally advised about the importance of changing life–style as recommended by current international guidelines. At T0, pts in the TR group performed a 500m moderate and perceptually–regulated (11–13 on the 6–20 Borg scale) treadmill walking test (500–m TWT) to estimate peak oxygen uptake (VO2peak). A home–based physical activity based on walking, was provided to pts in the TR group: it was recommended to maintain the level of perceived intensity of effort as indicated during 500m–TWT. These pts also received a reinforce phone–call at 2 and 4 weeks (T1 and T2), that allowed monitoring the adherence to the programme. All pts were finally evaluated 8 weeks after enrollment (T3) through the same tests performed at T0.
Results
Pts of the TR group at T3 reported significative improvement, compared to T0, in 6MWT (+79 m, p < 0.001), QoL (expressed in the items of SF12), usual physical activity during free time (+13MET/h/week, p < 0.001), VO2peak (+4 mL/kg/min, p < 0.001). Compliance to the programme resulted optimal since all TR group pts continued the planned physical activity for all the follow–up.
Conclusions
Results of this study on efficacy, feasibility and compliance of a new model of secondary prevention programme, suggest the importance of implementing programmes of tailored physical activity schedules, based on walking, that can be safetly started soon after clinical stabilization of ACS.
Collapse
Affiliation(s)
- R Lordi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - S Veronese
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - S Mandini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Raisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Piccinini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - A Ferro
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - V Zerbini
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - T Piva
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - G Grazzi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - S Biagio
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| | - G Pasanisi
- CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA; DEPARTMENT OF EMERGENCY, DIVISION OF CARDIAC REHABILITATION, AUSL FERRARA, LAGOSANTO; CENTRE FOR EXERCISE SCIENCE AND SPORT, UNIVERSITY OF FERRARA, FERRARA, PUBLIC HEALTH DEPARTMENT, AUSL FERRARA, FERRARA; DEPARTMENT OF MORPHOLOGY, SURGERY AND EXPERIMENTAL MEDICINE, UNIVERSITY OF FERRARA, FERRARA, DEPARTMENT OF EMERGENCY, DIVI
| |
Collapse
|
15
|
Pretelli G, Pavan A, Dal Maso A, Resi M, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato G, Frega S, Pasello G, Conte P, Guarneri V, Bonanno L. 63P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): Neutrophil to lymphocyte ratio (NLR) and the risk for toxicity recurrence. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.072] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
16
|
Gaio E, Ferro A, Lampasi A, Maistrello A, Dan M, Falvo M, Gasparini F, Lunardon F, Magnanimo A, Manganelli M, Minucci S, Panella S, Proietti Cosimi M, Ratti D, Barucca L, Ciattaglia S, Franke T, Federici G, Piovan R. Status and challenges for the concept design development of the EU DEMO Plant Electrical System. Fusion Engineering and Design 2022. [DOI: 10.1016/j.fusengdes.2022.113052] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
|
17
|
Pretelli G, Pavan A, Dal Maso A, Resi M, Mulargiu C, Ferro A, Benetti B, Lorenzi M, Marinato G, Frega S, Pasello G, Conte P, Guarneri V, Bonanno L. 40P Immune-related adverse events (irAEs) in advanced non-small cell lung cancer (aNSCLC) patients (pts): A real-world analysis. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
18
|
Ferro A, Sepulcri M, Schiavon M, Scagliori E, Gennaro G, Costa M, Bonanno L, Frega S, Dal Maso A, Calabrese F, Rea F, Caumo F, Guarneri V, Pasello G. 119P Evolution of the management of stage III non-small cell lung cancer (NSCLC): A single-center real-world scenario over 10 years. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.02.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022] Open
|
19
|
Ferro A, Kotecha S, Auzinger G, Yeung E, Fan K. Systematic review and meta-analysis of tracheostomy outcomes in COVID-19 patients. Br J Oral Maxillofac Surg 2021; 59:1013-1023. [PMID: 34294476 PMCID: PMC8130586 DOI: 10.1016/j.bjoms.2021.05.011] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2021] [Accepted: 05/07/2021] [Indexed: 01/04/2023]
Abstract
A systematic review and meta-analysis of the entire COVID-19 Tracheostomy cohort was conducted to determine the cumulative incidence of complications, mortality, time to decannulation and ventilatory weaning. Outcomes of surgical versus percutaneous and outcomes relative to tracheostomy timing were also analysed. Studies reporting outcome data on patients with COVID-19 undergoing tracheostomy were identified and screened by 2 independent reviewers. Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines were followed. Outcome data were analysed using a random-effects model. From 1016 unique studies, 39 articles reporting outcomes for a total of 3929 patients were included for meta-analysis. Weighted mean follow-up time was 42.03±26 days post-tracheostomy. Meta-analysis showed that 61.2% of patients were weaned from mechanical ventilation [95%CI 52.6%-69.5%], 44.2% of patients were decannulated [95%CI 33.96%-54.67%], and cumulative mortality was found to be 19.23% [95%CI 15.2%-23.6%] across the entire tracheostomy cohort. The cumulative incidence of complications was 14.24% [95%CI 9.6%-19.6%], with bleeding accounting for 52% of all complications. No difference was found in incidence of mortality (RR1.96; p=0.34), decannulation (RR1.35, p=0.27), complications (RR0.75, p=0.09) and time to decannulation (SMD 0.46, p=0.68) between percutaneous and surgical tracheostomy. Moreover, no difference was found in mortality (RR1.57, p=0.43) between early and late tracheostomy, and timing of tracheostomy did not predict time to decannulation. Ten confirmed nosocomial staff infections were reported from 1398 tracheostomies. This study provides an overview of outcomes of tracheostomy in COVID-19 patients, and contributes to our understanding of tracheostomy decisions in this patient cohort.
Collapse
Affiliation(s)
- A. Ferro
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, Denmark Hill, SE1 9RT London, United Kingdom
| | - S. Kotecha
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, Denmark Hill, SE1 9RT London, United Kingdom
| | - G. Auzinger
- Liver Intensive Care Unit, Department of Critical Care, King's College Hospital NHS Foundation Trust, Denmark Hill, SE1 9RT London, United Kingdom
| | - E. Yeung
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, Denmark Hill, SE1 9RT London, United Kingdom
| | - K. Fan
- Oral and Maxillofacial Surgery Department, King's College Hospital NHS Foundation Trust, Denmark Hill, SE1 9RT London, United Kingdom,Corresponding author at: King's College Hospital NHS Foundation Trust, Denmark Hill, London SE5 9RS, United Kingdom. Tel.: +4420 3299 5754
| |
Collapse
|
20
|
Ferro A, Basyuni S, Bosley R, Santhanam V. A predictive model for swallowing dysfunction after oral cancer resection. Br J Oral Maxillofac Surg 2021; 59:1043-1049. [PMID: 34563355 DOI: 10.1016/j.bjoms.2021.01.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2020] [Accepted: 01/22/2021] [Indexed: 12/24/2022]
Abstract
Aggressive therapy of oral cancers is associated with significant postoperative morbidity. Patients with feeding issues may require nutritional support. In our unit, patients identified as developing feeding issues are reactively referred for specialist input through a feeding issues multidisciplinary team meeting (FiMDT). Reactive feeding increases length of patient stay (LOS) and may contribute to patient morbidity. We aimed to develop a model to pre-emptively identify patients likely to develop feeding issues postoperatively, to facilitate the establishment of a preoperative referral pathway to increase patient flow. All referrals to a Head and Neck multidisciplinary team meeting over a five-year period were identified and preoperative factors were extracted. Linear regression was used to confirm that FiMDT was an independent predictor of LOS. Logistic regression was used to determine if referral to FiMDT could be predicted based on preoperative factors only. A total of 203 patients met inclusion criteria for analysis. Inpatient referral to FiMDT was an independent predictor of LOS. Significant predictors of inpatient FiMDT referral included tracheostomy, patient age, and alcohol intake. The resulting model was 90% sensitive and 93.8% specific with a threshold of 0.2. We have shown that inpatient FiMDT referral is an independent predictor of patient length of stay, and that the odds of referral can be robustly predicted. We aim to use this model in redirecting emphasis to a preoperative referral pathway for improved patient flow.
Collapse
Affiliation(s)
- A Ferro
- Department of Oral and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, United Kingdom.
| | - S Basyuni
- Department of Oral and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, United Kingdom
| | - R Bosley
- Department of Oral and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, United Kingdom
| | - V Santhanam
- Department of Oral and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust, Cambridge Biomedical Campus, Hills Road, Cambridge, CB2 0QQ, United Kingdom
| |
Collapse
|
21
|
Kapur M, Shah RA, Ferro A, Basyuni S, Brassett C, Santhanam V. Sexual dimorphism and geographical variance: their impact on the reliability of the antilingula as a landmark in human mandibular surgery. Br J Oral Maxillofac Surg 2021; 59:898-904. [PMID: 34420783 DOI: 10.1016/j.bjoms.2020.08.024] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/23/2019] [Accepted: 08/11/2020] [Indexed: 10/23/2022]
Abstract
The intraoral vertical ramus osteotomy (IVRO) is an orthognathic procedure that is used to correct dentofacial abnormalities, and is performed by approaching the lateral aspect of the mandibular ramus. This approach, however, precludes visualisation of the inferior alveolar nerve (IAN) on the medial side, thereby placing it at risk of iatrogenic damage. The antilingula, a bony prominence on the lateral mandibular ramus, has been proposed as a landmark for prediction of the IAN's location during IVRO. The current study aimed to evaluate the variation in incidence and position of the antilingula, and therefore to determine its suitability as a surgical landmark during IVRO. The study included 480 dry hemimandibles from eight geographical populations from the Duckworth Collection in Cambridge. Skulls were sexed by visual analysis of dimorphic traits. Positional relations were determined through the digitisation of nine anatomical landmarks. The antilingula was identified in all specimens. No significant difference was identified in the positional relation between the antilingula and mandibular foramen between sexes, but multiple differences were identified in this relation between geographical populations. Our data showed that, irrespective of geographical variation, an osteotomy performed 8mm posterior to the antilingula would avoid the mandibular foramen in 98.8% of cases.
Collapse
Affiliation(s)
- M Kapur
- School of Clinical Medicine, University of Cambridge, CB2 0SP, United Kingdom.
| | - R A Shah
- School of Clinical Medicine, University of Cambridge, CB2 0SP, United Kingdom.
| | - A Ferro
- School of Clinical Medicine, University of Cambridge, CB2 0SP, United Kingdom
| | - S Basyuni
- School of Clinical Medicine, University of Cambridge, CB2 0SP, United Kingdom
| | - C Brassett
- Human Anatomy Teaching Group, Department of Physiology, Development & Neuroscience, Downing Site, University of Cambridge, CB2 3DY, United Kingdom
| | - V Santhanam
- Department of Oral and Maxillofacial Surgery, Cambridge University Hospitals NHS Foundation Trust, Hills Road, Cambridge, CB2 0QQ, United Kingdom
| |
Collapse
|
22
|
Ferro A, Auguste YSS, Cheadle L. Microglia, Cytokines, and Neural Activity: Unexpected Interactions in Brain Development and Function. Front Immunol 2021; 12:703527. [PMID: 34276699 PMCID: PMC8281303 DOI: 10.3389/fimmu.2021.703527] [Citation(s) in RCA: 34] [Impact Index Per Article: 11.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Accepted: 06/11/2021] [Indexed: 12/01/2022] Open
Abstract
Intercellular signaling molecules such as cytokines and their receptors enable immune cells to communicate with one another and their surrounding microenvironments. Emerging evidence suggests that the same signaling pathways that regulate inflammatory responses to injury and disease outside of the brain also play powerful roles in brain development, plasticity, and function. These observations raise the question of how the same signaling molecules can play such distinct roles in peripheral tissues compared to the central nervous system, a system previously thought to be largely protected from inflammatory signaling. Here, we review evidence that the specialized roles of immune signaling molecules such as cytokines in the brain are to a large extent shaped by neural activity, a key feature of the brain that reflects active communication between neurons at synapses. We discuss the known mechanisms through which microglia, the resident immune cells of the brain, respond to increases and decreases in activity by engaging classical inflammatory signaling cascades to assemble, remodel, and eliminate synapses across the lifespan. We integrate evidence from (1) in vivo imaging studies of microglia-neuron interactions, (2) developmental studies across multiple neural circuits, and (3) molecular studies of activity-dependent gene expression in microglia and neurons to highlight the specific roles of activity in defining immune pathway function in the brain. Given that the repurposing of signaling pathways across different tissues may be an important evolutionary strategy to overcome the limited size of the genome, understanding how cytokine function is established and maintained in the brain could lead to key insights into neurological health and disease.
Collapse
Affiliation(s)
| | | | - Lucas Cheadle
- Neuroscience Department, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, United States
| |
Collapse
|
23
|
Toigo V, Marcuzzi D, Serianni G, Boldrin M, Chitarin G, Bello SD, Grando L, Luchetta A, Pasqualotto R, Zaccaria P, Zanotto L, Agnello R, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Berton G, Bigi M, Brombin M, Candeloro V, Canton A, Casagrande R, Cavallini C, Cavazzana R, Cordaro L, Cruz N, Palma MD, Dan M, De Lorenzi A, Delogu R, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gasparini F, Gasparrini C, Gnesotto F, Jain P, Krastev P, Lopez-Bruna D, Lorenzini R, Maistrello A, Manduchi G, Manfrin S, Marconato N, Martines E, Martini G, Martini S, Milazzo R, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Poggi C, Pomaro N, Pouradier-Duteil B, Recchia M, Rigoni-Garola A, Rizzolo A, Sartori E, Shepherd A, Siragusa M, Sonato P, Sottocornola A, Spada E, Spagnolo S, Spolaore M, Taliercio C, Terranova D, Tinti P, Tomsič P, Trevisan L, Ugoletti M, Valente M, Vignando M, Zagorski R, Zamengo A, Zaniol B, Zaupa M, Zuin M, Cavenago M, Boilson D, Rotti C, Veltri P, Decamps H, Dremel M, Graceffa J, Geli F, Urbani M, Zacks J, Bonicelli T, Paolucci F, Garbuglia A, Agarici G, Gomez G, Gutierrez D, Kouzmenko G, Labate C, Masiello A, Mico G, Moreno JF, Pilard V, Rousseau A, Simon M, Kashiwagi M, Tobari H, Watanabe K, Maejima T, Kojima A, Oshita E, Yamashita Y, Konno S, Singh M, Chakraborty A, Patel H, Singh N, Fantz U, Bonomo F, Cristofaro S, Heinemann B, Kraus W, Wimmer C, Wünderlich D, Fubiani G, Tsumori K, Croci G, Gorini G, McCormack O, Muraro A, Rebai M, Tardocchi M, Giacomelli L, Rigamonti D, Taccogna F, Bruno D, Rutigliano M, D'Arienzo M, Tonti A, Panin F. On the road to ITER NBIs: SPIDER improvement after first operation and MITICA construction progress. Fusion Engineering and Design 2021. [DOI: 10.1016/j.fusengdes.2021.112622] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
24
|
Lorenzi M, Dal Maso A, Ferro A, Polo V, Scattolin D, Macerelli M, Follador A, Targato G, Indraccolo S, Frega S, Menis J, Bonanno L, Guarneri V, Conte P, Pasello G. 149P First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW). J Thorac Oncol 2021. [DOI: 10.1016/s1556-0864(21)01991-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
25
|
Bordin P, Melot B, Tralli V, Bertoni C, Moretti F, Siddu A, Baldo V, Bonanni P, Castiglia P, Majori S, Ferro A. Six years of activity of the Italian vaccine portal "VaccinarSì": a web traffic evaluation using Google Analytics. Ann Ig 2021; 33:109-122. [PMID: 33570083 DOI: 10.7416/ai.2021.2417] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
BACKGROUND Despite the scientific consensus about vaccines safety and effectiveness, there is still a discrepancy between scientific evidence and perception by the general population. The "VaccinarSì" portal was created in 2013 by Italian specialists in Public Health to provide evidence-based information regarding vaccination. STUDY DESIGN The purpose of this study was to analyse the web traffic on "VaccinarSì" platform during a six-year period (May 8, 2013-May 8, 2019). Moreover, we compared the first six-month with the last six-month period of the website activity, to identify potential areas of improvements. METHODS This is a descriptive study using Google Analytics data. We collected data regarding the following: total number of sessions to the portal, total number of pages viewed, total number of users and the number of new visitors, geographical locations and demography of users as well as user access mode (type of device used and way of access). We also collected some data that were informative about the possibility to infer the level of visitors' engagement with the portal, such as thee number of returning users, bounce rate, number of pages visited per session and mean session duration. RESULTS Throughout the relevant period, the portal has consistently increased its popularity, with a remarkable increment of monthly connections (ending up to more than 80,000/month) from all over Italy. Visitors were mainly female (71.1%), aged between 25 and 44 years (64.7%). Healthcare professionals were responsible for a considerable proportion of accesses (50.6%). The mobile has become the dominant device used to access the portal, accounting for 77.8% of total connection in the last six months. Similarly, in the last period, organic search accounted for 92% of all connections. Measles and MPR vaccine, as well as chickenpox and hexavalent vaccine, have remained the most appealing topics of interest among visitors over the years. The page that attracted more visitors over the six years was "real risks and benefits of vaccination", accounting for 5.67% of total sessions with a high mean duration spent of 05:08 minutes. CONCLUSION During the six years of activity, overall, the level of users' engagement with the portal has dropped with an increased bounce rate and a lower average number of pages visited per session and a lower mean duration of each connection. The lowest engagement involved connections accessed through mobile devices. Results helped "Vaccinarsi" developers to speculate about future strategies to further increase the platform popularity and optimize visitors' engagement.
Collapse
Affiliation(s)
- P Bordin
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - B Melot
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - V Tralli
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - C Bertoni
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - F Moretti
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - A Siddu
- Department of Prevention, AULSS 3, Bassano del Grappa, Vicenza, Italy
| | - V Baldo
- Department of Cardiological, Thoracic and Vascular Sciences and Public Health. Hygiene and Public Health Unit, University of Padua, Italy
| | - P Bonanni
- Department of Health Sciences, University of Florence, Italy
| | - P Castiglia
- Department of Medical Surgical and Experimental Sciences, University of Sassari, Italy
| | - S Majori
- Department of Public Health and Community Medicine, Hygiene and Environmental, Occupational and Preventive Medicine Division, University of Verona, Verona, Italy
| | - A Ferro
- Department of Prevention, APSS Trento, Italy
| |
Collapse
|
26
|
Choo S, Mhatre S, Ferro A, Machado R, Liu DC, Irahara N, Gaillard V, Shao YY. 180P Real-world (RW) treatment (tx) patterns and outcomes in patients (pts) from Taiwan and Singapore with intermediate and advanced hepatocellular carcinoma (HCC). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.10.201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022] Open
|
27
|
Nuciforo P, Townend J, Saura C, de Azumbaja E, Hilbers F, Manukyants A, Werutsky G, Bliss J, Moebus V, Colleoni M, Aspitia A, Di Cosimo S, Van dooren V, Kroep J, Ferro A, Cameron D, Gelber R, Piccart-Gebhart M, Huober J. Nine-year survival outcome of neoadjuvant lapatinib with trastuzumab for HER2-positive breast cancer (NeoALTTO, BIG 1-06): final analysis of a multicentre, open-label, phase 3 randomised clinical trial. Eur J Cancer 2020. [DOI: 10.1016/s0959-8049(20)30560-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
28
|
Maso AD, Ferro A, Lorenzi M, Polo V, Scattolin D, Del Conte A, Scoccia E, Frega S, Bonanno L, Indraccolo S, Calabrese F, Guarneri V, Conte P, Pasello G. 1398P Real-life progression (PD) pattern of EGFR mutant advanced non-small cell lung cancer (aNSCLC) patients (pts) receiving systemic therapy after first- or second-generation tyrosine kinase inhibitor (1-2 gen TKI). Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022] Open
|
29
|
Thirunavukarasu AJ, Ferro A, Singh Dubb S, Hamilton DL, Brassett C. Investigating the correlation between bone density and fracture frequency in the mandibular condyle with micro-computed tomography. Br J Oral Maxillofac Surg 2020; 59:380-383. [PMID: 33495045 DOI: 10.1016/j.bjoms.2020.08.097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 08/15/2020] [Indexed: 11/26/2022]
Abstract
Fractures of the mandibular condyle are common and include diacapitular fractures that affect the condylar head. The medial part of the condylar head is least commonly fractured, possibly due to decreased propensity for lines of force to run in the region. Micro-computed tomography (X-ray microtomography) of five temporomandibular joint specimens was conducted to explore whether trabecular bone structure correlates positively with fracture prevalence, which could reflect adaptation in response to lower exposure to physiological loads throughout life. Models of trabecular bone, and graphic representation of bone density indicated least dense bone medially, but a statistically significant ANOVA result was not obtained. Further study is required to verify whether a relationship between bone microstructure and fracture frequency exists, and whether or not this is the product of association between the directions of physiological and traumatic forces.
Collapse
Affiliation(s)
- A J Thirunavukarasu
- Corpus Christi College, University of Cambridge, United Kingdom; Human Anatomy Centre, Anatomy Building, Department of Physiology, Development and Neuroscience, University of Cambridge, United Kingdom.
| | - A Ferro
- Department of Oral and Maxillofacial Surgery, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - S Singh Dubb
- Department of Oral and Maxillofacial Surgery, Addenbrooke's Hospital, Cambridge, United Kingdom
| | - D L Hamilton
- Department of Anaesthesia, James Cook University Hospital, Middlesbrough, United Kingdom; University of Sunderland School of Medicine, Sunderland, United Kingdom
| | - C Brassett
- Human Anatomy Centre, Anatomy Building, Department of Physiology, Development and Neuroscience, University of Cambridge, United Kingdom
| |
Collapse
|
30
|
Gaio E, Ferro A, Maistrello A, Dan M, Lunardon F, Barucca L, Ciattaglia S, Federici G, Benfatto I. The EU DEMO Plant Electrical System: Issues and perspective. Fusion Engineering and Design 2020. [DOI: 10.1016/j.fusengdes.2020.111728] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
31
|
Ferro A, Bordin P, Benacchio L, Fornasiero F, Bressan V, Tralli V, Moretti F, Majori S. Influenza vaccination and absenteeism among healthy working adults: a cost-benefit analysis. Ann Ig 2020; 32:234-244. [PMID: 32266361 DOI: 10.7416/ai.2020.2346] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
BACKGROUND Seasonal influenza is a highly contagious infection that might lead to serious clinical complications and incurs a conspicuous socio-economic impact. Influenza vaccination is currently recommended only for specific groups of healthy adults (such as healthcare workers) even though it was demonstrated to be effective in reducing absenteeism and decreased workers' productivity during flu epidemic period. The main purpose of this study is to analyse the extent of absences due to illness following a voluntary flu immunization program among the Komatsu Italia Manufacturing company's personnel during the flu season 2017-2018. Secondly, we aimed at performing a cost-benefit analysis of the vaccination campaign from the company's perspective. STUDY DESIGN This is an observational cohort study conducted during the period between the 14th week of 2017 and the 13th week of 2018 (from 03/04/2017 to 01/04/2018). The study population was the personnel of Komatsu Italia Manufacturing S.p.A. on duty during the study period. METHODS For each subject the following data were collected: sex, date of birth, professional profile, seasonal influenza immunization status and sick-leave days. Sick-leave days were compared among the influenza epidemic period and the previous one between vaccinated and unvaccinated and any difference in days of absence was considered to be caused by seasonal influenza. RESULTS Out of 408 employees, 60 (14.7%) accepted the voluntary influenza vaccination. In multivariate analysis (logistic model) an age ≥ 50 years was the only predictor for vaccination acceptance (ORM 3.11 p<0.001). During the flu period, the monthly mean of sick-leave days per employee was significantly lower among the vaccinated than the unvaccinated, respectively of 0.328 days/person vs 0.752 days/person (p = 0.022). Unvaccinated employees reported a higher average of sick-leave days during the flu period compared to the previous non-influenza period (0.752 days/month/person vs 0.337 days/month/person p <0.001). The monthly mean cost for sickness absences per employee was significantly higher for an unvaccinated subject compared to one vaccinated, respectively € 129.00 and € 54.00 (p = 0.028). The overall net saving estimated was € 314.00 per person vaccinated. CONCLUSIONS Influenza vaccination proved to be an extraordinary preventive tool and a cost-effective intervention. However, influenza immunization seems to be unappealing among healthy adults and higher flu vaccination coverages could be achieved through educational interventions possibly addressing young employees who showed little interest in vaccination. Finally, among health promotion interventions, companies should point out the importance of flu vaccination both for the individual wellbeing and the company environment.
Collapse
Affiliation(s)
- A Ferro
- Department of Prevention, APSS Trento, Italy
| | - P Bordin
- Postgraduate School of Hygiene and Preventive Medicine, Department of Diagnostics and Public Health, University of Verona, Italy
| | - L Benacchio
- Department of Prevention, Service of Epidemiology, AULSS 6 Euganea, Padua, Italy
| | - F Fornasiero
- Department of Prevention, Service of Epidemiology, AULSS 6 Euganea, Padua, Italy
| | - V Bressan
- Department of Prevention, Service of Epidemiology, AULSS 6 Euganea, Padua, ItalyDepartment of Prevention, Service of Epidemiology, AULSS 6 Euganea, Padua, Italy
| | - V Tralli
- Postgraduate School of Hygiene and Preventive Medicine, Department of Diagnostics and Public Health, University of Verona, Italy
| | - F Moretti
- Section of Hygiene and Preventive, Environmental and Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, Italy
| | - S Majori
- Section of Hygiene and Preventive, Environmental and Occupational Medicine, Department of Diagnostics and Public Health, University of Verona, Italy
| |
Collapse
|
32
|
Basyuni S, Ferro A, Santhanam V, Birch M, McCaskie A. Systematic scoping review of mandibular bone tissue engineering. Br J Oral Maxillofac Surg 2020; 58:632-642. [PMID: 32247521 DOI: 10.1016/j.bjoms.2020.03.016] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2019] [Accepted: 03/14/2020] [Indexed: 12/12/2022]
Abstract
Tissue engineering is a promising alternative that may facilitate bony regeneration in small defects in compromised host tissue as well as large mandibular defects. This scoping systematic review was therefore designed to assess in vivo research on its use in the reconstruction of mandibular defects in animal models. A total of 4524 articles were initially retrieved using the search algorithm. After screening of the titles and abstracts, 269 full texts were retrieved, and a total of 72 studies included. Just two of the included studies employed osteonecrosis as the model of mandibular injury. All the rest involved the creation of a critical defect. Calcium phosphates, especially tricalcium phosphate and hydroxyapatite, were the scaffolds most widely used. All the studies that used a scaffold reported increased formation of bone when compared with negative controls. When combined with scaffolds, mesenchymal stem cells (MSC) increased the formation of new bone and improved healing. Various growth factors have been studied for their potential use in the regeneration of the maxillofacial complex. Bone morphogenic proteins (BMP) were the most popular, and all subtypes promoted significant formation of bone compared with controls. Whilst the studies published to date suggest a promising future, our review has shown that several shortfalls must be addressed before the findings can be translated into clinical practice. A greater understanding of the underlying cellular and molecular mechanisms is required to identify the optimal combination of components that are needed for predictable and feasible reconstruction or regeneration of mandibular bone. In particular, a greater understanding of the biological aspects of the regenerative triad is needed before we can to work towards widespread translation into clinical practice.
Collapse
Affiliation(s)
- S Basyuni
- Department of Oral and Maxillo-Facial Surgery, Cambridge University Hospitals, Cambridge, United Kingdom; Department of Surgery, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
| | - A Ferro
- Department of Oral and Maxillo-Facial Surgery, Cambridge University Hospitals, Cambridge, United Kingdom.
| | - V Santhanam
- Department of Oral and Maxillo-Facial Surgery, Cambridge University Hospitals, Cambridge, United Kingdom.
| | - M Birch
- Department of Surgery, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
| | - A McCaskie
- Department of Surgery, School of Clinical Medicine, University of Cambridge, Cambridge, United Kingdom.
| |
Collapse
|
33
|
Dieci MV, Conte P, Bisagni G, Brandes AA, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Piacentini F, Maiorana A, Orvieto E, Sanders M, Miglietta F, Balduzzi S, D'Amico R, Guarneri V. Association of tumor-infiltrating lymphocytes with distant disease-free survival in the ShortHER randomized adjuvant trial for patients with early HER2+ breast cancer. Ann Oncol 2020; 30:418-423. [PMID: 30657852 PMCID: PMC6442655 DOI: 10.1093/annonc/mdz007] [Citation(s) in RCA: 59] [Impact Index Per Article: 14.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022] Open
Abstract
BACKGROUND There is the need to identify new prognostic markers to refine risk stratification for HER2-positive early breast cancer patients. The aim of this study was to evaluate the association of tumor-infiltrating lymphocytes (TILs) with distant disease-free survival (DDFS) in patients with HER2-positive early breast cancer enrolled in the ShortHER adjuvant trial which compared 9 weeks versus 1-year trastuzumab in addition to chemotherapy, and to test the interaction between TILs and treatment arm. PATIENTS AND METHODS Stromal TILs were assessed for 866 cases on centralized hematoxylin and eosin-stained tumor slides. The association of TILs as 10% increments with DDFS was assessed with Cox models. Kaplan-Meier curves were estimated for patients with TILs ≥20% and TILs <20%. Median follow-up was 6.1 years. RESULTS Median TILs was 5% (Q1-Q3 1%-15%). Increased TILs were independently associated with better DDFS in multivariable model [hazard ratio (HR) 0.73, 95% confidence interval (CI) 0.59-0.89, P = 0.006, for each 10% TILs increment]. Five years DDFS rates were 91.1% for patients with TILs <20% and 95.7% for patients with TILs ≥20% (P = 0.025). The association between 10% TILs increments and DDFS was significant for patients randomized to 9 weeks of trastuzumab (HR 0.60, 95% CI 0.41-0.88) but not for patients treated with 1 year of trastuzumab (HR 0.89, 95% CI 0.71-1.12; test for interaction P = 0.088). For patients with TILs <20%, the HR for the comparison between the short versus the long arm was 1.75 (95% CI 1.09-2.80, P=0.021); whereas, for patients with TILs ≥20% the HR for the comparison of short versus long arm was 0.23 (95% CI 0.05-1.09, P = 0.064), resulting in a significant interaction (P = 0.015). CONCLUSIONS TILs are an independent prognostic factor for HER2-positive early breast cancer patients treated with adjuvant chemotherapy and trastuzumab and may refine the ability to identify patients at low risk of relapse eligible for de-escalated adjuvant therapy.
Collapse
Affiliation(s)
- M V Dieci
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
| | - P Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova.
| | - G Bisagni
- Oncology Unit, Department of Oncology and Advanced Technologies, Azienda USL-IRCCS, Reggio Emilia
| | - A A Brandes
- Medical Oncology, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna
| | - A Frassoldati
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara
| | - L Cavanna
- Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza
| | - A Musolino
- Medical Oncology Unit, University Hospital of Parma, Piacenza
| | - F Giotta
- Division of Medical Oncology, IRCCS, Istituto Tumori "Giovanni Paolo II", Bari
| | - A Rimanti
- Medical Oncology, Azienda Ospedaliera di Mantova, Mantova
| | - O Garrone
- Medical Oncology, A.O. S. Croce and Carle Teaching Hospital, Cuneo
| | - E Bertone
- Medical Oncology, S. Anna Hospital, Torino
| | - K Cagossi
- Breast Unit Ausl Modena, Ramazzini Hospital, Carpi
| | - S Sarti
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola
| | - A Ferro
- Rete Clinica Senologica - Oncologia Medica S. Chiara, Trento
| | - F Piacentini
- Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena; Azienda Ospedaliero-Universitaria di Modena, Modena
| | - A Maiorana
- Department of Diagnostic, Clinical Medicine and Public Health, University Hospital of Modena, Modena
| | - E Orvieto
- Pathology Unit, Ulss 5 Polesana, Rovigo, Italy
| | - M Sanders
- Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center, Nashville, USA
| | - F Miglietta
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova
| | - S Balduzzi
- Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Italy
| | - R D'Amico
- Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Medical Oncology 2, Istituto Oncologico Veneto IRCCS, Padova
| |
Collapse
|
34
|
Serianni G, Toigo V, Bigi M, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Marcuzzi D, Pasqualotto R, Pomaro N, Zaccaria P, Zanotto L, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Brombin M, Canton A, Cavazzana R, Dalla Palma M, Dan M, Delogu R, De Lorenzi A, De Muri M, Denizeau S, Fadone M, Fellin F, Ferro A, Gaio E, Gambetta G, Gasparini F, Gnesotto F, Jain P, Maistrello A, Manduchi G, Manfrin S, Marchiori G, Marconato N, Moresco M, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Piovan R, Poggi C, Recchia M, Rigoni A, Rizzolo A, Rostagni G, Sartori E, Siragusa M, Sonato P, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Ugoletti M, Valente M, Zamengo A, Zaniol B, Zaupa M, Cavenago M, Boilson D, Rotti C, Veltri P, Chareyre J, Decamps H, Dremel M, Graceffa J, Geli F, Schunke B, Svensson L, Urbani M, Bonicelli T, Agarici G, Garbuglia A, Masiello A, Paolucci F, Simon M, Bailly-Maitre L, Bragulat E, Gomez G, Gutierrez D, Labate C, Mico G, Moreno JF, Pilard V, Kouzmenko G, Rousseau A, Chakraborty A, Baruah U, Patel H, Singh NP, Patel A, Dhola H, Raval B, Cristofaro S, Fantz U, Heinemann B, Kraus W, Kashiwagi M, Tobari H. First operation in SPIDER and the path to complete MITICA. Rev Sci Instrum 2020; 91:023510. [PMID: 32113382 DOI: 10.1063/1.5133076] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2019] [Accepted: 01/22/2020] [Indexed: 06/10/2023]
Abstract
The requirements of ITER neutral beam injectors (1 MeV, 40 A negative deuterium ion current for 1 h) have never been simultaneously attained; therefore, a dedicated Neutral Beam Test Facility (NBTF) was set up at Consorzio RFX (Padova, Italy). The NBTF includes two experiments: SPIDER (Source for the Production of Ions of Deuterium Extracted from Rf plasma), the full-scale prototype of the source of ITER injectors, with a 100 keV accelerator, to investigate and optimize the properties of the ion source; and MITICA, the full-scale prototype of the entire injector, devoted to the issues related to the accelerator, including voltage holding at low gas pressure. The present paper gives an account of the status of the procurements, of the timeline, and of the voltage holding tests and experiments for MITICA. As for SPIDER, the first year of operation is described, regarding the solution of some issues connected with the radiofrequency power, the source operation, and the characterization of the first negative ion beam.
Collapse
Affiliation(s)
- G Serianni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Toigo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Bigi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Boldrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Chitarin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Dal Bello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Grando
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Luchetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Marcuzzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Pasqualotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pomaro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Zaccaria
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - L Zanotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Agostinetti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Agostini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - V Antoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - D Aprile
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Barbisan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Battistella
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Brombin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Canton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Cavazzana
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dalla Palma
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Dan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Delogu
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A De Lorenzi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M De Muri
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Denizeau
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Fadone
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Fellin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Ferro
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Gaio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Gambetta
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gasparini
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - F Gnesotto
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Jain
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Maistrello
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Manduchi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Manfrin
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Marchiori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Marconato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Moresco
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - T Patton
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Pavei
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Peruzzo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - N Pilan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Pimazzoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - R Piovan
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Poggi
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Recchia
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rigoni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Rizzolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - G Rostagni
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Sartori
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Siragusa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Sonato
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - E Spada
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - S Spagnolo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Spolaore
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - C Taliercio
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - P Tinti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Ugoletti
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Valente
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - A Zamengo
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - B Zaniol
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Zaupa
- Consorzio RFX (CNR, ENEA, INFN, UNIPD, Acciaierie Venete SpA), Corso Stati Uniti 4, 35127 Padova, Italy
| | - M Cavenago
- INFN-Laboratori Nazionali di Legnaro (LNL), v.le dell'Università 2, I-35020 Legnaro, PD, Italy
| | - D Boilson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - C Rotti
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - P Veltri
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Chareyre
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - H Decamps
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Dremel
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - J Graceffa
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - F Geli
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - B Schunke
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - L Svensson
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - M Urbani
- ITER Organization, Route de Vinon-sur-Verdon, CS 90 046, F-13067 St. Paul-lez-Durance, France
| | - T Bonicelli
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Agarici
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Garbuglia
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Masiello
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - F Paolucci
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - M Simon
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - L Bailly-Maitre
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - E Bragulat
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Gomez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - D Gutierrez
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - C Labate
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Mico
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - J F Moreno
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - V Pilard
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - G Kouzmenko
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Rousseau
- Fusion for Energy, C/o Josep Pla 2, E-08019 Barcelona, Spain
| | - A Chakraborty
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - U Baruah
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - N P Singh
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - A Patel
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - H Dhola
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - B Raval
- ITER-India, Institute for Plasma Research, Nr. Indira Bridge, Bhat Village, Gandhinagar, Gujarat 382428, India
| | - S Cristofaro
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - U Fantz
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - B Heinemann
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - W Kraus
- IPP, Max-Planck-Institut für Plasmaphysik, Boltzmannstraße 2, D-85748 Garching bei München, Germany
| | - M Kashiwagi
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| | - H Tobari
- National Institutes for Quantum and Radiological Science and Technology, 801-1 Mukoyama, Naka, Ibaraki-ken 311-0193, Japan
| |
Collapse
|
35
|
Gangemi CMA, Alaimo S, Pulvirenti A, García-Viñuales S, Milardi D, Falanga AP, Fragalà ME, Oliviero G, Piccialli G, Borbone N, Ferro A, D'Urso A, Croce CM, Purrello R. Endogenous and artificial miRNAs explore a rich variety of conformations: a potential relationship between secondary structure and biological functionality. Sci Rep 2020; 10:453. [PMID: 31949213 PMCID: PMC6965629 DOI: 10.1038/s41598-019-57289-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/04/2019] [Accepted: 12/23/2019] [Indexed: 12/22/2022] Open
Abstract
Mature microRNAs are short non-coding RNA sequences which upon incorporation into the RISC ribonucleoprotein complex, play a crucial role in regulation of gene expression. However, miRNAs can exist within the cell also as free molecules fulfilling their biological activity. Therefore, it is emerging that in addition to sequence even the structure adopted by mature miRNAs might play an important role to reach the target. Indeed, we analysed by several spectroscopic techniques the secondary structures of two artificial miRNAs selected by computational tool (miR-Synth) as best candidates to silence c-MET and EGFR genes and of two endogenous miRNAs (miR-15a and miR-15b) having the same seed region, but different biological activity. Our results demonstrate that both endogenous and artificial miRNAs can arrange in several 3D-structures which affect their activity and selectivity toward the targets.
Collapse
Affiliation(s)
- C M A Gangemi
- Department of Chemical Science, University of Catania, Viale A. Doria 6, 95125, Catania, Italy
| | - S Alaimo
- Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy c/o Department of Mathematics and Computer Science, Viale A. Doria 6, 95125, Catania, Italy
| | - A Pulvirenti
- Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy c/o Department of Mathematics and Computer Science, Viale A. Doria 6, 95125, Catania, Italy
| | | | - D Milardi
- Istituto di Cristallografia CNR, Via P. Gaifami 9, 95126, Catania, Italy
| | - A P Falanga
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - M E Fragalà
- Department of Chemical Science, University of Catania, Viale A. Doria 6, 95125, Catania, Italy
| | - G Oliviero
- Department of Molecular Medicine and Medical Biotechnologies, University of Naples Federico II, Via Pansini 5, 80131, Napoli, Italy
| | - G Piccialli
- Department of Pharmacy, University of Naples Federico II, D. Montesano 49, 80131, Napoli, Italy
| | - N Borbone
- Department of Pharmacy, University of Naples Federico II, D. Montesano 49, 80131, Napoli, Italy
| | - A Ferro
- Bioinformatics Unit, Department of Clinical and Experimental Medicine, University of Catania, Italy c/o Department of Mathematics and Computer Science, Viale A. Doria 6, 95125, Catania, Italy.
| | - A D'Urso
- Department of Chemical Science, University of Catania, Viale A. Doria 6, 95125, Catania, Italy.
| | - C M Croce
- Department of Molecular Virology, Immunology and Medical Genetics, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, 43210, USA
| | - R Purrello
- Department of Chemical Science, University of Catania, Viale A. Doria 6, 95125, Catania, Italy.
| |
Collapse
|
36
|
Melillo E, Palmiero G, Ferro A, Carlomagno G, Dell"urzo L, Ascione R, Caso VM, Severino S, Ascione L, Caso P. P664 Relationship of left atrial function assessed by 2D speckle tracking echocardiography with left ventricular systolic function in patients with degenerative mitral regurgitation. Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.344] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
none
Background
In degenerative mitral regurgitation (DMR), left ventricle (LV) and left atrium (LA) undergo progressive volume overload leading to chamber remodelling and dysfunction in advanced stages. Speckle tracking echocardiography (STE) is an estabilished technique able in detecting subclinical LA and LV dysfunction in this setting. However data are lacking on the relationship of LA and LV function in DMR patients.
Purpose
Our aim was to assess LA function in patients with DMR and to explore its possible correlations with LV dimensions and systolic function.
Methods
We enrolled 95 patients with mild to severe DMR, dichotomizing them on the basis of mitral regurgitation severity (DMR 1-2: mild and mild-to-moderate MR; DMR 3-4: at least moderate to severe MR). LA function was assesed with 2D speckle tracking echocardiography.
Results
The two groups were well matched. DMR 3-4 group (n= 48) showed higher LA and LV volumes, lower right ventricle longitudinal systolic function and higher values of systolic pulmonary pressure. There was not significant difference in LV ejection fraction (LVEF) and global longitudinal strain (GLS). Among LA function indexes, only peak systolic reservoir strain was significantly reduced in DMR 3-4 group (21,9± 6,2% vs 24,7± 7,2% ; p= 0,04). Then population study was further divided in two groups according to the presence (LA dys+) or absence (LA dys-) of LA dysfunction, defined as reservoir strain values below the median [median 23.7%; LAdys- group (n. 49), LAdys+ group (n.46) ]. At the comparison of continuous variables (Tab.1), LAdys+ group showed larger LV end systolic diameter and more impaired LVEF (60,9± 9,8% vs 65,4± 4,8%; p: 0,004) and GLS (20,04 ± 3,7% vs 23,53 ± 2,7%; p <0,001).
Conclusions
Our data showed that LA reservoir strain was impaired in patients with moderate to severe DMR. Furthermore, patients with LA dysfunction showed reduced LVEF and GLS values. Consequently, LA dysfunction assessed with STE may be a novel marker of early LV systolic dysfunction in patients with degenerative mitral regurgitation.
Tab.1 LAdysf- (n = 49) LAdysf+ (n = 46) P value LVESD (mm) 31.78 ± 4.1 34.74 ± 7.6 0.020 LAVI (mL/mq) 44.5 ± 15.1 55.6 ± 25.6 0.015 TAPSE (mm) 26.30 ± 3.96 24.02 ± 3.31 0.004 sPAP (mmHg) 31.4 ± 7.0 36.4 ± 10.9 0.009 LVEF (%) 65.4 ± 4.8 60.9 ± 9.8 0.004 GLS (%) 23.5 ± 2.7 20.0 ± 3.7 <0.001 Comparison of continuous variables between patients with and without LA dysfunction.
Collapse
Affiliation(s)
- E Melillo
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - G Palmiero
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - A Ferro
- National Research Council, Institute of Biostructure and Bioimages, Naples, Italy
| | | | - L Dell"urzo
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - R Ascione
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - V M Caso
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - S Severino
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - L Ascione
- AO dei Colli-Monaldi Hospital, Naples, Italy
| | - P Caso
- AO dei Colli-Monaldi Hospital, Naples, Italy
| |
Collapse
|
37
|
Conte P, Frassoldati A, Bisagni G, Brandes AA, Donadio M, Garrone O, Piacentini F, Cavanna L, Giotta F, Aieta M, Gebbia V, Molino A, Musolino A, Ferro A, Maltoni R, Danese S, Zamagni C, Rimanti A, Cagossi K, Russo A, Pronzato P, Giovanardi F, Moretti G, Lombardo L, Schirone A, Beano A, Amaducci L, Bajardi EA, Vicini R, Balduzzi S, D'Amico R, Guarneri V. Nine weeks versus 1 year adjuvant trastuzumab in combination with chemotherapy: final results of the phase III randomized Short-HER study‡. Ann Oncol 2019; 29:2328-2333. [PMID: 30219886 DOI: 10.1093/annonc/mdy414] [Citation(s) in RCA: 100] [Impact Index Per Article: 20.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Chemotherapy plus 1-year trastuzumab is the standard adjuvant treatment of HER2-positive breast cancer. The efficacy of less extended trastuzumab exposure is under investigation. The short-HER study was aimed to assess the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy. Patients and methods HER2-positive breast cancer patients with node-positive or, if node negative, with at least one risk factor (pT>2 cm, G3, lympho-vascular invasion, Ki-67 > 20%, age ≤35 years, or hormone receptor negativity) were randomly assigned to receive sequential anthracycline-taxane combinations plus 1-year trastuzumab (arm A, long) or plus 9 weeks trastuzumab (arm B, short). This study was designed as a non-inferiority trial with disease-free survival (DFS) as primary end point. A DFS hazard ratio (HR) <1.29 was chosen as the non-inferiority margin. Analyses according to the frequentist and Bayesian approach were planned. Secondary end points included 2-year failure rate and cardiac safety. Results A total of 1254 patients from 82 centers were randomized (arm A, long: n = 627; arm B, short: n = 626). Five-year DFS is 88% in the long and 85% in the short arm. The HR is 1.13 (90% CI 0.89-1.42), with the upper limit of the CI crossing the non-inferiority margin. According to the Bayesian analysis, the probability that the short arm is non-inferior to the long one is 80%. The 5-year overall survival (OS) is 95.2% in the long and 95.0% in the short arm (HR 1.07, 90% CI 0.74-1.56). Cardiac events are significantly lower in the short arm (risk-ratio 0.33, 95% CI 0.22-0.50, P < 0.0001). Conclusions This study failed to show the non-inferiority of a shorter trastuzumab administration. One-year trastuzumab remains the standard. However, a 9-week administration decreases the risk of severe cardiac toxicity and can be an option for patients with cardiac events during treatment and for those with a low risk of relapse. Trial Registration EUDRACT number: 2007-004326-25; NCI ClinicalTrials.gov number: NCT00629278.
Collapse
Affiliation(s)
- P Conte
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy.
| | - A Frassoldati
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara, Italy
| | - G Bisagni
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - A A Brandes
- Medical Oncology, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - M Donadio
- Department of Medical Oncology 1, Città della Salute e della Scienza Hospital, Turin, Italy
| | - O Garrone
- Medical Oncology, A.O. S. Croce and Carle Teaching Hospital, Cuneo, Italy
| | - F Piacentini
- Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy; Azienda Ospedaliero-Universitaria di Modena, Modena, Italy
| | - L Cavanna
- Department of Oncology-Hematology, G. da Saliceto Hospital, Piacenza, Italy
| | - F Giotta
- Division of Medical Oncology, IRCCS, Giovanni Paolo II Hospital, Bari, Italy
| | - M Aieta
- Division of Medical Oncology, IRCCS-CROB, Referral Cancer Center of Basilicata, Rionero Vulture (PZ), Italy
| | - V Gebbia
- Medical Oncology, Casa di Cura La Maddalena, University of Palermo, Palermo, Italy
| | - A Molino
- Oncology Unit, Verona University Hospital, Verona, Italy
| | - A Musolino
- Medical Oncology Unit, University Hospital of Parma, Parma, Italy
| | - A Ferro
- Medical Oncology, Santa Chiara Hospital, Trento, Italy
| | - R Maltoni
- Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, IRST, IRCCS, Meldola, Italy
| | - S Danese
- Department of Gynecology and Obstetrics, Ospedale S. Anna, Turin, Italy
| | - C Zamagni
- Policlinico S.Orsola-Malpighi, SSD Oncologia Medica Addarii, Bologna, Italy
| | - A Rimanti
- Medical Oncology, Azienda Ospedaliera Carlo Poma, Mantova, Italy
| | - K Cagossi
- Division of Medical Oncology, "B.Ramazzini" Hospital, Carpi, Italy
| | - A Russo
- Section of Medical Oncology, Department of Surgical and Oncological Sciences, University of Palermo, Palermo, Italy
| | - P Pronzato
- Department of Medical Oncology, U.O. Oncologia Medica 2, IRCCS AOU San Martino-IST, Genova, Italy
| | - F Giovanardi
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - G Moretti
- Department of Oncology and Advanced Technologies, Oncology Unit, IRCCS Arcispedale Santa Maria Nuova, Reggio Emilia, Italy
| | - L Lombardo
- Medical Oncology, Azienda Unità Sanitaria Locale di Bologna-IRCCS Istituto delle Scienze Neurologiche, Bologna, Italy
| | - A Schirone
- Clinical Oncology, Department of Morphology, Surgery and Experimental Medicine, S Anna University Hospital, Ferrara, Italy
| | - A Beano
- Department of Medical Oncology 1, Città della Salute e della Scienza Hospital, Turin, Italy
| | - L Amaducci
- Medical Oncology Unit, Ospedale degli Infermi Faenza, Faenza, Italy
| | - E A Bajardi
- Medical Oncology, Casa di Cura La Maddalena, University of Palermo, Palermo, Italy
| | - R Vicini
- Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - S Balduzzi
- Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - R D'Amico
- Azienda Ospedaliero-Universitaria di Modena, Modena, Italy; Department of Diagnostic and Clinical Medicine and Public Health, Statistics Unit, University Hospital of Modena and Reggio Emilia, Modena, Italy
| | - V Guarneri
- Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy; Medical Oncology 2, Istituto Oncologico Veneto (IOV), IRCCS, Padova, Italy
| |
Collapse
|
38
|
Abstract
Microglial inflammation is often seen as a secondary event in neurodegeneration. A recent study by Song et al. demonstrates that loss of ataxia telangiectasia mutated (ATM) activates microglia through the cytosolic DNA sensor STING. This highlights the ability of microglia to recognize and respond to self-DNA, with potentially neurotoxic consequences.
Collapse
Affiliation(s)
- Austin Ferro
- Department of Neuroscience, University of Minnesota, 2101 6th Street South East, Minneapolis, MN 55455, USA
| | - Carrie Sheeler
- Department of Neuroscience, University of Minnesota, 2101 6th Street South East, Minneapolis, MN 55455, USA
| | - Marija Cvetanovic
- Department of Neuroscience, University of Minnesota, 2101 6th Street South East, Minneapolis, MN 55455, USA; Institute for Translational Neuroscience, University of Minnesota, 2101 6th Street South East, Minneapolis, MN 55455, USA.
| |
Collapse
|
39
|
Bonanno L, Pavan A, Ferro A, Calvetti L, Frega S, Pasello G, Aprile G, Guarneri V, Conte P. Clinical impact of plasma next-generation sequencing (NGS) in advanced non-small cell lung cancer (aNSCLC). Ann Oncol 2019. [DOI: 10.1093/annonc/mdz257.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
40
|
De Laurentiis M, Mazza M, Mansutti M, Masetti R, Ballatore Z, Torrisi R, Michelotti A, Zambelli A, Ferro A, Generali D, Vici P, Coltelli L, Fabi A, Marchetti P, Ballestrero A, Spazzapan S, Frassoldati A, Sarobba G, Grasso D, Zamagni C. Safety and efficacy of ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz242.030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
41
|
Serianni G, Toigo V, Bigi M, Boldrin M, Chitarin G, Dal Bello S, Grando L, Luchetta A, Marcuzzi D, Pasqualotto R, Pomaro N, Zaccaria P, Zanotto L, Agostinetti P, Agostini M, Antoni V, Aprile D, Barbisan M, Battistella M, Brombin M, Cavazzana R, Dalla Palma M, Dan M, De Lorenzi A, Delogu R, De Muri M, Denizeau S, Fadone M, Fellin F, Ferbel L, Ferro A, Gaio E, Gambetta G, Gasparini F, Gnesotto F, Jain P, Maistrello A, Manduchi G, Manfrin S, Marchiori G, Marconato N, Moresco M, Patton T, Pavei M, Peruzzo S, Pilan N, Pimazzoni A, Piovan R, Poggi C, Recchia M, Rizzolo A, Rostagni G, Sartori E, Siragusa M, Sonato P, Spada E, Spagnolo S, Spolaore M, Taliercio C, Tinti P, Ugoletti M, Valente M, Zamengo A, Zaniol B, Zaupa M, Baltador C, Cavenago M, Boilson D, Rotti C, Veltri P, Bonicelli T, Paolucci F, Muriel S, Masiello A, Chakraborty A, Patel H, Singh N, Fantz U, Heinemann B, Kraus W, Kashiwagi M, Tsumori K. SPIDER in the roadmap of the ITER neutral beams. Fusion Engineering and Design 2019. [DOI: 10.1016/j.fusengdes.2019.04.036] [Citation(s) in RCA: 28] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
42
|
Abstract
Microglia, the resident macrophages of the central nervous system, critically influence neural function during development and in adulthood. Microglia are also profoundly sensitive to insults to the brain to which they respond with process of activation that includes spectrum of changes in morphology, function, and gene expression. Ataxias are a class of neurodegenerative diseases characterized by motor discoordination and predominant cerebellar involvement. In case of inherited forms of ataxia, mutant proteins are expressed throughout the brain and it is unclear why cerebellum is particularly vulnerable. Recent studies demonstrated that cerebellar microglia have a uniquely hyper-vigilant immune phenotype compared to microglia from other brain regions. These findings may indicate that microglia actively contribute to cerebellar vulnerability in ataxias. Here we review current knowledge about cerebellar microglia, their activation, and their role in the pathogenesis of ataxias. In addition, we briefly review advantages and disadvantages of several experimental approaches available to study microglia.
Collapse
Affiliation(s)
- Austin Ferro
- Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
| | - Carrie Sheeler
- Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
| | - Juao-Guilherme Rosa
- Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
| | - Marija Cvetanovic
- Department of Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA; Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN 55455, USA.
| |
Collapse
|
43
|
Mellesmoen A, Sheeler C, Ferro A, Rainwater O, Cvetanovic M. Brain Derived Neurotrophic Factor (BDNF) Delays Onset of Pathogenesis in Transgenic Mouse Model of Spinocerebellar Ataxia Type 1 (SCA1). Front Cell Neurosci 2019; 12:509. [PMID: 30718999 PMCID: PMC6348256 DOI: 10.3389/fncel.2018.00509] [Citation(s) in RCA: 27] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2018] [Accepted: 12/10/2018] [Indexed: 12/19/2022] Open
Abstract
Spinocerebellar ataxia type 1 (SCA1) is a fatal neurodegenerative disease caused by an abnormal expansion of CAG repeats in the Ataxin-1 (ATXN1) gene and characterized by motor deficits and cerebellar neurodegeneration. Even though mutant ATXN1 is expressed from an early age, disease onset usually occurs in patient’s mid-thirties, indicating the presence of compensatory factors that limit the toxic effects of mutant ATXN1 early in disease. Brain derived neurotrophic factor (BDNF) is a growth factor known to be important for the survival and function of cerebellar neurons. Using gene expression analysis, we observed altered BDNF expression in the cerebella of Purkinje neuron specific transgenic mouse model of SCA1, ATXN1[82Q] mice, with increased expression during the early stage and decreased expression in the late stage of disease. We therefore investigated the potentially protective role of BDNF in early stage SCA1 through intraventricular delivery of BDNF via ALZET osmotic pumps. Extrinsic BDNF delivery delayed onset of motor deficits and Purkinje neuron pathology in ATXN1[82Q] mice supporting its use as a novel therapeutic for SCA1.
Collapse
Affiliation(s)
- Aaron Mellesmoen
- Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States
| | - Carrie Sheeler
- Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States
| | - Austin Ferro
- Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States
| | - Orion Rainwater
- Department of Lab Medicine and Pathology, University of Minnesota, Minneapolis, MN, United States
| | - Marija Cvetanovic
- Department of Neuroscience, University of Minnesota, Minneapolis, MN, United States.,Institute for Translational Neuroscience, University of Minnesota, Minneapolis, MN, United States
| |
Collapse
|
44
|
Fonzo M, Ferro A, Ferraresso A, Mascarello M, Minascurta V, Pistellato I, Cabbia C, Baldovin T, Baldo V, Bertoncello C. LTBI in migrants: tolerability of isoniazid monotherapy and combination of isoniazid and rifampicin. Eur J Public Health 2018. [DOI: 10.1093/eurpub/cky213.171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- M Fonzo
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - A Ferro
- Public Health Department, AULSS 6 Este, Padova, Italy
| | - A Ferraresso
- Public Health Department, AULSS 6 Este, Padova, Italy
| | - M Mascarello
- Public Health Department, AULSS 6 Este, Padova, Italy
| | - V Minascurta
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - I Pistellato
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - C Cabbia
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - T Baldovin
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - V Baldo
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| | - C Bertoncello
- DCTV - Hygiene and Public Health Unit, University of Padova, Padova, Italy
| |
Collapse
|
45
|
Dieci M, Conte P, Bisagni G, Brandes A, Frassoldati A, Cavanna L, Musolino A, Giotta F, Rimanti A, Garrone O, Bertone E, Cagossi K, Sarti S, Ferro A, Omarini C, Maiorana A, Orvieto E, Sanders M, D'Amico R, Guarneri V. Tumor-infiltrating lymphocytes (TILs) as an independent prognostic factor for early HER2+ breast cancer patients treated with adjuvant chemotherapy and trastuzumab in the randomized shortHER trial. Ann Oncol 2018. [DOI: 10.1093/annonc/mdy270.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
46
|
Palmiero G, Melillo E, Ferro A, Ascione R, Ascione A, Carlomagno G, Monda V, Severino S, Caso P. P887Left atrial dysfunction as the main determinant of clinical status, right ventricular dysfunction and pulmonary hypertension in HFrEF patients with significant functional mitral regurgitation. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy564.p887] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- G Palmiero
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - E Melillo
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - A Ferro
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - R Ascione
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - A Ascione
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - G Carlomagno
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - V Monda
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - S Severino
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| | - P Caso
- AO dei Colli-Monaldi Hospital, Department of Cardiology, Naples, Italy
| |
Collapse
|
47
|
Ferro A, Qu W, Lukowicz A, Svedberg D, Johnson A, Cvetanovic M. Inhibition of NF-κB signaling in IKKβF/F;LysM Cre mice causes motor deficits but does not alter pathogenesis of Spinocerebellar ataxia type 1. PLoS One 2018; 13:e0200013. [PMID: 29975753 PMCID: PMC6033432 DOI: 10.1371/journal.pone.0200013] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2018] [Accepted: 06/18/2018] [Indexed: 12/21/2022] Open
Abstract
Spinocerebellar Ataxia type 1 (SCA1) is a fatal neurodegenerative genetic disease that is characterized by pronounced neuronal loss and gliosis in the cerebellum. We have previously demonstrated microglial activation, measured as an increase in microglial density in cerebellar cortex and an increase in the production of pro-inflammatory cytokines, including tumor necrosis factor alpha (TNF-α), in the cerebellum of the ATXN1[82Q] transgenic mouse model of SCA1. To examine the role of activated state of microglia in SCA1, we used a Cre-Lox approach with IKKβF/F;LysM Cre mice intended to reduce inflammatory NF-κB signaling, selectively in microglia. ATXN1[82Q];IKKβF/F;LysM Cre mice showed reduced cerebellar microglial density and production of TNFα compared to ATXN1[82Q] mice, yet reducing NF-κB did not ameliorate motor impairments and cerebellar cellular pathologies. Unexpectedly, at 12 weeks of age, control IKKβF/F;LysM Cre mice showed motor deficits equal to ATXN1[82Q] mice that were dissociated from any obvious neurodegenerative changes in the cerebellum, but were rather associated with a developmental impairment that presented as a retention of climbing fiber synaptic terminals on the soma of Purkinje neurons. These results indicate that NF-κB signaling is required for increase in microglial numbers and TNF-α production in the cerebella of ATXN1[82Q] mouse model of SCA1. Furthermore, these results elucidate a novel role of canonical NF-κB signaling in pruning of surplus synapses on Purkinje neurons in the cerebellum during development.
Collapse
Affiliation(s)
- Austin Ferro
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Wenhui Qu
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Abigail Lukowicz
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Daniel Svedberg
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Andrea Johnson
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| | - Marija Cvetanovic
- Department of Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
- Institute for Translational Neuroscience, University of Minnesota, Minneapolis, Minnesota, United States of America
| |
Collapse
|
48
|
Maló P, Lopes A, de Araújo Nobre M, Ferro A. Immediate function dental implants inserted with less than 30N·cm of torque in full-arch maxillary rehabilitations using the All-on-4 concept: retrospective study. Int J Oral Maxillofac Surg 2018; 47:1079-1085. [PMID: 29735198 DOI: 10.1016/j.ijom.2018.04.008] [Citation(s) in RCA: 20] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2017] [Revised: 02/26/2018] [Accepted: 04/09/2018] [Indexed: 11/26/2022]
Abstract
The aim of this retrospective clinical study was to evaluate the short-term implant success rate and marginal bone loss in full-arch fixed prosthetic maxillary rehabilitations supported by implants in immediate function with the All-on-4 treatment concept placed with insertion torque of <30N·cm or ≥30N·cm. This study included 83 patients (69 female, 14 male) with 332 implants placed (120 inserted with <30N·cm and 212 inserted with ≥30N·cm) who were treated between January 2010 and March 2013. Outcome measures were implant success and marginal bone loss at 1year of follow-up. Ten patients (12.0%; 13 implants inserted with <30N·cm and 27 implants with ≥30N·cm) were lost to follow-up. The cumulative implant success rate was 97.5% at the patient level, and 98.3% for implants inserted with <30N·cm and 97.5% for implants inserted with ≥30N·cm. The mean±standard deviation marginal bone loss at 1year was 1.14±0.38mm for implants inserted with <30N·cm and 1.39±0.49mm for implants inserted with ≥30N·cm (significant difference; P<0.001, Wilcoxon signed rank test). These results indicate that implants with insertion torques of <30N·cm may render comparable success rates and marginal bone loss at 1year compared to implants inserted with insertion torques of ≥30N·cm.
Collapse
Affiliation(s)
- P Maló
- Oral Surgery Department, Maló Clinic, Lisbon, Portugal
| | - A Lopes
- Oral Surgery Department, Maló Clinic, Lisbon, Portugal
| | | | - A Ferro
- Oral Surgery Department, Maló Clinic, Lisbon, Portugal
| |
Collapse
|
49
|
|
50
|
Benasso M, Ferro A, Bacigalupo A, Toma S, Vitriolo S, Rosso R, Merlano M. Analysis of 16 Patients with Metastatic Squamous Cell Carcinoma of the Head and Neck: Implications for Treatment. Tumori 2018; 75:597-9. [PMID: 2617704 DOI: 10.1177/030089168907500617] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
Abstract
The present paper reports a retrospective analysis of 16 patients with distant metastases from squamous cell carcinoma of the head and neck observed in our Institute in the last 10 years. Nine patients out of 16 underwent chemotherapy (7 patients), chemotherapy and radiotherapy (1 patient), or an alternating chemo-radiotherapy regimen (1 patient). The remaining 7 patients were not considered for a palliative treatment because of a poor performance status. Two complete responses, 2 partial responses, 2 stable diseases and 3 progressions were observed, with an overall response rate of 44 %. Chemotherapy, when administrable, showed a temporary effectiveness, at least in patients with lung metastases. The combination of cisplatin and 5-fluorouracil seems to maintain the efficacy already shown in patients with locally relapsed disease.
Collapse
Affiliation(s)
- M Benasso
- Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy
| | | | | | | | | | | | | |
Collapse
|